Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.56 |
| ▸ | BACE1 | P56817 | 3/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18087495 | 1.00 | CASP1 (0.63) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL24310825 | 1.00 | CASP1 (0.63) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL812941 | 0.91 | CASP1 (0.61) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL23931322 | 0.91 | CASP1 (0.61) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL29932500 | 0.90 | CASP1 (0.63) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL31047238 | 0.90 | CASP1 (0.56) | CASP1OPRD1BACE1BACE2REN | |
| SCHEMBL27825824 | 0.90 | CASP1 (0.67) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL9241543 | 0.90 | CASP1 (0.67) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL29030118 | 0.89 | CASP1 (0.64) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL6691650 | 0.88 | CASP1 (0.62) | CASP1OPRD1BACE1BACE2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240263210-A1 | METHODS FOR ENZYMATIC PEPTIDE LIGATION | UNIV NANYANG TECH (SG) | 2024-08-08 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3515931-B1 | METHODS FOR ENZYMATIC PEPTIDE LIGATION | UNIV NANYANG TECH (SG) | 2024-05-01 | — | — | EP | disclosed |
| CN-109790205-B | Method for enzymatic peptide ligation | 南洋理工大学 | 2024-01-16 | — | — | CN | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11795488-B2 | Methods for enzymatic peptide ligation | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-10-24 | — | — | US | disclosed |
| US-20230128192-A1 | METHODS FOR ENZYMATIC PEPTIDE LIGATION | UNIV NANYANG TECH (SG) | 2023-04-27 | — | — | US | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| EP-3366302-A1 | PROTECTION OF CELLS FROM ALU-RNA-INDUCED DEGENERATION AND INHIBITORS FOR PROTECTING CELLS | University Of Kentucky Research Foundation (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2734240-B1 | PROTECTION OF CELLS FROM ALU-RNA-INDUCED DEGENEREATION AND INHIBITORS FOR PROTECTING CELLS | UNIV KENTUCKY RES FOUND (US) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885OPRD1 4792/4885BACE1 2824/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885OPRD1 4792/4885BACE1 2824/4885 |
| US-20240263210-A1 | METHODS FOR ENZYMATIC PEPTIDE LIGATION | XPNPEP1, LIG1, NGLY1 | CASP1 617/4885OPRD1 1670/4885BACE1 434/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885OPRD1 4792/4885BACE1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.